[1]潘金 袁博 张一凡 陈艳 王敏.溃疡性结肠炎的心血管疾病危险因素分析[J].心血管病学进展,2021,(11):1046-1051.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
 PAN Jin,YUAN Bo,ZHANG Yifan,et al.Risk Factors of Cardiovascular Disease in Patients with Ulcerative Colitis[J].Advances in Cardiovascular Diseases,2021,(11):1046-1051.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
点击复制

溃疡性结肠炎的心血管疾病危险因素分析()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年11期
页码:
1046-1051
栏目:
论著
出版日期:
2021-11-25

文章信息/Info

Title:
Risk Factors of Cardiovascular Disease in Patients with Ulcerative Colitis
文章编号:
202103001
作者:
潘金 袁博 张一凡 陈艳 王敏
(西安市第九医院心血管内科,陕西 西安 710054)
Author(s):
PAN JinYUAN BoZHANG YifanCHEN YanWANG Min
(Department of Vasculocardiology,Xi’an Ninth Hospital,Xi’an 710054,Shaanxi,China)
关键词:
溃疡性结肠炎心血管疾病危险因素血浆纤维蛋白原同型半胱氨酸
Keywords:
Ulcerative colitisCardiovascular diseaseRisk factorPlasma fibrinogenHomocysteine
DOI:
10.16806/j.cnki.issn.1004-3934.2021.11.000
摘要:
目的 分析溃疡性结肠炎(UC)患者发生心血管疾病(CVD)的危险因素。方法 回顾性分析西安市第九医院2016年2月—2019年6月收治的208例UC患者的临床病历资料,按是否发生CVD将这208例UC患者分为单纯UC组(n=133)和UC合并CVD组(n=75),比较两组患者一般资料如性别、年龄和合并症等以及实验室各项检查结果,采用多因素逻辑回归分析UC患者发生CVD的危险因素。结果 208例UC患者发生CVD 75例,发生率为36.06%,UC患者CVD的发生与年龄、高血压、糖尿病和高脂血症有关(P<0.05);UC合并CVD组左心室收缩期末容积、左心室舒张期末容积以及N末端脑钠肽前体、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、D-二聚体(D-D)、纤维蛋白原(FIB)、白介素-1β、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)和同型半胱氨酸(Hcy)高于单纯UC组(P<0.05),左室射血分数以及高密度脂蛋白胆固醇、活化部分凝血活酶时间、凝血酶原时间和凝血酶时间低于单纯UC组(P<0.05);逻辑回归分析提示年龄≥65岁(OR=1.689,P=0.013)、高血压(OR=1.988,P=0.001)、糖尿病(OR=1.850,P=0.009)、高脂血症(OR=1.885,P=0.009)、FIB(OR=1.782,P=0.019)、D-D(OR=1.624,P=0.007)、hs-CRP(OR=1.542,P=0.029)、TNF-α(OR=1.654,P=0.007)和Hcy(OR=1.644,P=0.021)是UC患者发生CVD的独立危险因素,差异具有统计学意义(P<0.05)。结论 高龄、高血压、糖尿病、高脂血症以及FIB、D-D、hs-CRP、TNF-α、Hcy高水平可能对UC患者发生CVD有一定影响。
Abstract:
Objective To analyze the risk factors of cardiovascular disease(CVD) in patients with ulcerative colitis(UC). Methods We retrospectively analyzed the clinical records of 208 UC patients admitted to Xi’an Ninth Hospital between February 2016 and June 2019. According to whether CVD occurred,they were divided into simple UC group(n=133) and UC-CVD group(n=75). The general data (gender,age,comorbidities) and laboratory test results were compared between the two groups. The risk factors of CVD in UC patients were analyzed by multivariate logistic regression. Results Among the 208 UC patients,there were 75 cases(36.06%) with CVD. The occurrence of CVD in UC patients was related to age,hypertension,diabetes and hyperlipidemia(P<0.05). The left ventricular end-systolic volume,left ventricular end-diastolic volume,N-terminal pro-brain natriuretic peptide,total cholesterol,triglycerides,low-density lipoprotein cholesterol,D-dimer (D-D),fibrinogen(FIB),interleukin-1β,high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α) and homocysteine(Hcy) in UC-CVD group were higher than those in simple UC group(P<0.05),while left ventricular ejection fraction,high-density lipoprotein cholesterol,activated partial thromboplastin time,prothrombin time and thrombin time were lower than those in simple UC group(P<0.05). Logistic regression analysis indicated that age not younger than 65 years old(OR=1.689,P=0.013),hypertension(OR=1.988,P=0.001),diabetes(OR=1.850,P=0.009),hyperlipidemia(OR=1.885,P=0.009),FIB(OR=1.782,P=0.019),D-D(OR=1.624,P=0.007),hs-CRP(OR=1.542,P=0.029),TNF-α(OR=1.654,P=0.007) and Hcy(OR=1.644,P=0.021) were independent risk factors of CVD in UC patients(P<0.05). Conclusion There may be certain effects of elderly age,hypertension,diabetes,hyperlipidemia,high levels of FIB,D-D,hs-CRP,TNF-α and Hcy on the occurrence of CVD in UC patients

参考文献/References:

[1]Fukuda T,Naganuma M,Sugimoto S,et al. The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy:a report from the IBD registry[J]. PLoS One,2017,12(11):e0187737.
[2]Spagnuolo R,Dattilo V,D’Antona L,et al. Deregulation of SGK1 in ulcerative colitis:a paradoxical relationship between immune cells and colonic epithelial cells[J]. Inflamm Bowel Dis,2018,24(9):1967-1977.
[3]郑慧怡,马芙蓉,罗晓清,等. 牛初乳通过调节肠道菌群对小鼠溃疡性结肠炎的改善作用[J]. 中南医学科学杂志,2020,48(5):531-535.
[4]Song EM,Lee HS,Park SH,et al. Clinical characteristics and long-term prognosis of elderly onset ulcerative colitis[J]. J Gastroenterol Hepatol,2018,33(1):172-179.
[5]Al-Talabany S,Mordi I,Graeme Houston J,et al. Epicardial adipose tissue is related to arterial stiffness and inflammation in patients with cardiovascular disease and type 2 diabetes[J]. BMC Cardiovasc Disord,2018,18(1):31.
[6]Barnes EL,Beery RM,Schulman AR,et al. Hospitalizations for acute myocardial infarction are decreased among patients with inflammatory bowel disease using a nationwide inpatient database[J]. Inflamm Bowel Dis,2016,22(9):2229-2237.
[7]Rahier JF,Magro F,Abreu C,et al. Second European evidence-based consensus on the prevention,diagnosis and management of opportunistic infections in inflammatory bowel disease[J]. J Crohns Colitis,2014,8(6):443-468.
[8]Garg M,Hendy P,Ding JN,et al. The effect of vitamin D on intestinal inflammation and faecal microbiota in patients with ulcerative colitis[J]. J Crohns Colitis,2018,12(8):963-972.
[9]Yan Y,Sun J,Xie X,et al. Colon-targeting mutual prodrugs of 5-aminosalicylic acid and butyrate for the treatment of ulcerative colitis[J]. RSC Advances,2018,8(5):2561-2574.
[10]Bermejo F,Aguas M,Chaparro M,et al. Recommendations of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis(GETECCU) on the use of thiopurines in inflammatory bowel disease[J]. Gastroenterol Hepatol,2018,41(3):205-221.
[11]Butler T,Kerley CP,Altieri N,et al. Optimum nutritional strategies for cardiovascular disease prevention and rehabilitation(BACPR)[J]. Heart,2020,106(10):724-731.
[12]Flora GD,Nayak MK. A brief review of cardiovascular diseases,associated risk factors and current treatment regimes[J]. Curr Pharm Des,2019,25(38):4063-4084.
[13]Triches CB,Mayer S,Quinto BMR,et al. Association of endothelial dysfunction with cardiovascular risk factors and new-onset diabetes mellitus in patients with hypertension[J]. J Clin Hypertens(Greenwich),2018,20(5):935-941.
[14]Liu W,Wang T,Sun P,et al. Expression of Hcy and blood lipid levels in serum of CHD patients and analysis of risk factors for CHD[J]. Exp Ther Med,2019,17(3):1756-1760.
[15]Shentova R,Yaneva P,Baycheva M,et al. Role of laboratory markers in paediatric inflammatory bowel disease[J]. J Crohns Colitis,2018,12(1):S456-S463.
[16]Canseco-Avila LM,Lopez-Roblero A,Serrano-Guzman E,et al. Polymorphisms -455G/A and -148C/T and fibrinogen plasmatic level as risk markers of coronary disease and major adverse cardiovascular events[J]. Dis Markers,2019,2019:5769514.
[17]Jang JY,Bae JS,Kang MG,et al. The impact of serial measurement of plasma fibrinogen and cardiovascular outcomes after percutaneous coronary intervention in patients with coronary artery disease[J]. Eur Heart J,2018,39(1):168-172
[18]Zhang C,Jia Y,Jia Y,et al. Prognostic and predictive value of plasma D-dimer levels in patients with small-cell lung cancer[J]. Int J Clin Oncol,2018,23(6):1070-1075.
[19]Chen M,Li Z,Zhang Z,et al. Intervention of integrative medicine treatment has impact on serum levels of ET-1,TNF-α,MLT in RA-CVD[J]. Saudi J Biol Sci,2018,25(5):959-964.
[20]Liu B,Xu L,Yu X,et al. Protective effect of KLF15 on vascular endothelial dysfunction induced by TNF-α[J]. Mol Med Rep,2018,18(2):1987-1994.
[21]Alánová P,Chytilová A,Necká? J,et al. Myocardial ischemic tolerance in rats subjected to endurance exercise training during adaptation to chronic hypoxia[J]. J Appl Physiol (1985),2017,122(6):1452-1461.
[22]Moretti R,Caruso P. The controversial role of homocysteine in neurology:from labs to clinical practice[J]. Int J Mol Sci,2019,20(1):231-251.
[23]Wang XJ,Tian DC,Wang FW,et al. Astaxanthin inhibits homocysteine-induced endothelial cell dysfunction via the regulation of the reactive oxygen species-dependent VEGF-VEGFR2-FAK signaling pathway[J]. Mol Med Rep,2019,19(6):4753-4760.
[24]Raffield LM,Ellis J,Olson NC,et al. Genome-wide association study of homocysteine in African Americans from the Jackson Heart Study,the Multi-Ethnic Study of Atherosclerosis,and the Coronary Artery Risk in Young Adults study[J]. J Hum Genet,2018,63(3):327-337.

相似文献/References:

[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
 BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(11):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
 REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(11):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
 YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
 ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
 QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
 JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
 HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(11):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
 Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(11):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
 WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(11):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]

备注/Memo

备注/Memo:
收稿日期:2021-03-01基金项目:西安市科技计划项目[2019114813YX003SF036(4)]通信作者:王敏,E-mail:luck121591@163.com
更新日期/Last Update: 2021-12-06